Meeting
2023 ASCO Annual Meeting
Associations between androgen-directed treatments and AR mutational landscapes in the circulating tumor DNA of a real-world metastatic prostate cancer cohort.
Authors
Elisa M. Ledet
Tulane University, New Orleans, LA
Elisa M. Ledet , Arockia Jayaraj , Ellen B. Jaeger , Melissa Conrad Stoppler , Minqi Huang , Calvin Y. Chao , A. Oliver Sartor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5061)
DOI
10.1200/JCO.2023.41.16_suppl.5061
Abstract #
5061
Poster Bd #
155
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 1b study of bavdegalutamide, an androgen receptor PROTAC degrader, combined with abiraterone in patients with metastatic prostate cancer.
First Author: Neal D. Shore
Poster
2024 ASCO Genitourinary Cancers Symposium
Somatostatin receptor 1 (SSTR1) expression as a potential predictive biomarker for response to androgen receptor signaling inhibitor (ARSI) therapy in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Xiaolin Zhu
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
First Author: Evan Y. Yu
Poster
2023 ASCO Annual Meeting
mFAST-SeqS based aneuploidy score in circulating cell-free DNA and role as early response marker in patients with metastatic prostate cancer treated with androgen receptor signaling inhibitor.
First Author: Khrystany T. Isebia